1. Home
  2. CRUS vs CRSP Comparison

CRUS vs CRSP Comparison

Compare CRUS & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cirrus Logic Inc.

CRUS

Cirrus Logic Inc.

HOLD

Current Price

$118.86

Market Cap

5.9B

Sector

Technology

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$52.49

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRUS
CRSP
Founded
1984
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.4B
IPO Year
1989
2016

Fundamental Metrics

Financial Performance
Metric
CRUS
CRSP
Price
$118.86
$52.49
Analyst Decision
Strong Buy
Buy
Analyst Count
5
19
Target Price
$140.00
$71.50
AVG Volume (30 Days)
436.3K
1.6M
Earning Date
02-03-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
19.23
N/A
EPS
7.02
N/A
Revenue
$1,948,426,000.00
$38,337,000.00
Revenue This Year
$0.95
N/A
Revenue Next Year
$1.88
$718.51
P/E Ratio
$16.87
N/A
Revenue Growth
2.19
N/A
52 Week Low
$75.83
$30.04
52 Week High
$136.92
$78.48

Technical Indicators

Market Signals
Indicator
CRUS
CRSP
Relative Strength Index (RSI) 42.29 39.25
Support Level $119.03 $53.76
Resistance Level $122.41 $59.18
Average True Range (ATR) 2.69 2.33
MACD -0.26 -0.28
Stochastic Oscillator 1.46 1.60

Price Performance

Historical Comparison
CRUS
CRSP

About CRUS Cirrus Logic Inc.

Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: